HTD1801 in Adults With Nonalcoholic Steatohepatitis and Liver Fibrosis Who Have Type 2 Diabetes or Pre-Diabetes
210 patients around the world
Available in Puerto Rico, United States, Mexico
This phase 2b, double-blind, randomized, placebo-controlled, multicenter study will evaluate
the effect of HTD1801, 1250 mg twice daily (BID) compared to placebo BID on histologic
improvements in adult subjects with non-alcoholic steatohepatitis and liver fibrosis who have
type 2 diabetes mellitus or pre-diabetes.
The study will enroll approximately 210 subjects with biopsy-confirmed non-alcoholic
steatohepatitis and evidence of stage 2 or stage 3 liver fibrosis. Subjects will receive
investigational product for up to 60 weeks.